Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir
(TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600
mg /100 mg twice daily) in combination with investigator selected optimised background
regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI),
Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI))
treatment-experienced (a minimum of 3-months duration for each class) with resistance to more
than one PI on the screening virtual phenotype resistance testing.